Use of a compound of general formula: or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof, in which: R 1 represents -(CH 2) n -(CHR 4)-(CH 2) m -N(R 5)(R 5'); R 2 represents a heteroaryl optionally substituted with 1, 2 or 3 R 6 groups; R 3 represents alkyl or cycloalkyl; R 4 represents hydrogen, hydroxy or alkoxy; R 5 and R 5 may be the same or different and are independently, hydrogen, alkyl, cycloalkylalklyl, or alkoxyalkyl or R 5 and R 5' may be taken together with the nitrogen atom to which they are bound to form a 3-7 membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more R 6 groups, or R 4 and R 5 may be taken together with the atoms to which they are bound to form a 5-6 membered nitrogen containing heterocyclic ring optionally containing 1 or more nitrogen, oxygen or sulfur atoms and which may be optionally substituted with 1 or more R 6' groups; each occurrence of R 6 may be the same or different and is independently halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalklyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic ring, heterocyclylalkyl, alkyl-OR 7, alkyl-SR 7, alkyl-N(R 7)(R 7'), alkyl-COR 7,-CN, - COOR 7, -CON(R 7)(R 7'), -OR 7, -SR 7, -N(R 7)(R 7'), or -NR 7 COR 7 each of which may be optionally substituted with 1 or more R 8 groups; each occurrence of R 6' may be the same or different and is independently alkyl, cycloalkylalklyl, or alkyl-OR 7; each occurrence of R 7 and R 7' may be the same or different and is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalklyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclic ring, heterocyclylalkyl, or heteroarylalkyl; each occurrence of R 8 is independently nitro, hydroxy, cyano, formyl, acetyl, halogen, amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalklyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclic ring, heterocyclylalkyl, or heteroarylalkyl; n is an integer from 1-4 and m is an integer from 0-4 with the proviso that when when R 4 and R 5 are taken together with the atoms to which they are bound to form a 3-7 membered nitrogen containing ring, n + m ≤ 4; for the preparation of a medicament for the treatment of multiple myeloma. R 1 represents -(CH 2) n -(CHR 4)-(CH 2) m -N(R 5)(R 5'); R 2 represents a heteroaryl optionally substituted with 1, 2 or 3 R 6 groups; R 3 represents alkyl or cycloalkyl; R 4 represents hydrogen, hydroxy or alkoxy; R 5 and R 5 may be the same or different and are independently, hydrogen, alkyl, cycloalkylalklyl, or alkoxyalkyl or R 5 and R 5' may be taken together with the nitrogen atom to which they are bound to form a 3-7 membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more R 6 groups, or R 4 and R 5 may be taken together with the atoms to which they are bound to form a 5-6 membered nitrogen containing heterocyclic ring optionally containing 1 or more nitrogen, oxygen or sulfur atoms and which may be optionally substituted with 1 or more R 6' groups;